Summary by Moomoo AI
NexImmune, a clinical stage biotechnology company, reported a net loss of $2.3 million for the three months ended June 30, 2024, a significant improvement from the $7.6 million net loss in the same period in 2023. Basic and diluted net loss per common share was $1.69 for the quarter, compared to $7.25 in the previous year. The company's research and development expenses decreased to $647,000 from $4.9 million year-on-year, reflecting a strategic shift in operations, including a reduction in force and a pause in clinical enrollment for certain product candidates. General and administrative expenses also saw a decrease to $2.1 million from $2.9 million. NexImmune has not generated any revenue from product sales and has an accumulated deficit of $228.0 million as of June 30, 2024. The company's cash and...Show More
